ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Daiichi Sankyo Co Ltd (PK)

Daiichi Sankyo Co Ltd (PK) (DSKYF)

32.125
1.63
(5.33%)
Closed November 03 4:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
32.125
Bid
31.15
Ask
32.90
Volume
4,465
32.089 Day's Range 33.35
25.72 52 Week Range 44.64
Market Cap
Previous Close
30.50
Open
33.19
Last Trade
161
@
32.125
Last Trade Time
Financial Volume
$ 143,702
VWAP
32.1842
Average Volume (3m)
2,884
Shares Outstanding
1,916,787,029
Dividend Yield
16,664.36%
PE Ratio
0.31
Earnings Per Share (EPS)
104.72
Revenue
1.63T
Net Profit
200.73B

About Daiichi Sankyo Co Ltd (PK)

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Biolog/vaccines
Headquarters
Chuo, Tokyo, Jpn
Founded
2005
Daiichi Sankyo Co Ltd (PK) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker DSKYF. The last closing price for Daiichi Sankyo (PK) was $30.50. Over the last year, Daiichi Sankyo (PK) shares have traded in a share price range of $ 25.72 to $ 44.64.

Daiichi Sankyo (PK) currently has 1,916,787,029 shares outstanding. The market capitalization of Daiichi Sankyo (PK) is $58.46 billion. Daiichi Sankyo (PK) has a price to earnings ratio (PE ratio) of 0.31.

DSKYF Latest News

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular ...

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent...

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge PR Newswire PARSIPPANY, N.J., April 1, 2015 PARSIPPANY, N.J., April 1, 2015 /PRNewswire/ -- Daiichi Sankyo, Inc., the US subsidiary of...

Venue Change

Tue, Oct 08, 2013 12:00 - Daiichi Sankyo Co., Ltd. (DSKYF: OTC Link) - Venue Change - The symbol, DSKYF, no longer trades on Grey Market. As of Tue, Oct 08, 2013, DSKYF trades on OTC Link. You...

Glaxo Files for Two Flu Vaccines - Analyst Blog

Recently, GlaxoSmithKline (GSK) announced that it has filed marketing applications for two influenza vaccines. The vaccines, up for approval, include a quadrivalent influenza vaccine for the...

Glaxo and Daiichi to Set Up JV - Analyst Blog

British drugmaker GlaxoSmithKline (GSK) recently announced that it has signed an agreement with Daiichi Sankyo (DSKYF) to form a joint venture (JV). The JV will be called Japan Vaccine Co., Ltd...

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources PR Newswire PARSIPPANY, N.J., June 28, 2011 PARSIPPANY, N.J., June 28, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc...

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc. PR Newswire PARSIPPANY, N.J., April 4, 2011 PARSIPPANY, N.J., April 4, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced...

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fib

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More Than 21,000 Patients Enrolled in the Largest...

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillatio

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More Than 21,000 Patients Enrolled in the Largest Clinical...

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology PR Newswire WOBURN, Massachusetts, October 12, 2010 WOBURN, Massachusetts, October 12, 2010 /PRNewswire/ -- ArQule, Inc...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.8656.1632518175830.2634.630.1237631.59077435CS
4-2.615-7.5273459988534.7435.3930.1298032.7736953CS
12-6.415-16.6450441138.5444.6430.1288436.03759527CS
26-2.145-6.2591187627734.2744.6430.1613334.95179476CS
525.90522.520976353926.2244.6425.721011631.56885086CS
1566.35524.660457896825.7744.6419.45795030.13089467CS
260-30.775-48.926868044562.995.9617.61617730.0963284CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BLIAQBB Liquidating Inc (CE)
$ 0.001
(99,900.00%)
102.03k
ERHEERHC Energy Inc (CE)
$ 0.001
(99,900.00%)
5.11M
GAPJGolden Apple Oil and Gas Inc (CE)
$ 0.001
(99,900.00%)
130
VIPZVIP Play Inc (PK)
$ 0.75
(62,400.00%)
300
FFRMFFuture Farm Technologies Inc (CE)
$ 0.000101
(10,000.00%)
1.25k
REPCFRepliCel Life Sciences Inc (CE)
$ 0.000001
(-99.98%)
2.5k
AHPIQAllied Healthcare Products Inc (CE)
$ 0.000001
(-99.50%)
1.16k
JUVAFJuva Life Inc (CE)
$ 0.000001
(-99.00%)
300
DXBRFBellRock Brands Inc (CE)
$ 0.000001
(-99.00%)
193.88k
MNGGMining Global Inc (PK)
$ 0.000001
(-99.00%)
4.7M
NSAVNet Savings Link Inc (PK)
$ 0.0006
(-68.42%)
1.1B
HMBLHUMBL Inc (PK)
$ 0.0003
(50.00%)
260.3M
RDARRaadr Inc (PK)
$ 0.001
(-9.09%)
214.52M
NNAXNew Momentum Corporation (PK)
$ 0.0006
(0.00%)
194.37M
ASIIAccredited Solutions Inc (PK)
$ 0.0009
(0.00%)
138.32M